Autoinflammatory diseases are a group of conditions in which the body’s immune system triggers inflammation on its own, without an infection or other external threat to fight. Unlike more familiar immune disorders, the problem lies specifically in the innate immune system, the fast-acting, first-line defense you’re born with. Instead of responding proportionally to danger, it fires off intense inflammatory signals unprovoked, causing recurring episodes of fever, pain, and organ damage.
Most autoinflammatory diseases are genetic, caused by mutations that leave inflammatory pathways permanently stuck in an “on” position. They are considered rare, though growing awareness and better genetic testing have led to more diagnoses in recent years. The International Union of Immunological Societies now classifies 576 distinct inborn errors of immunity, many of which fall on the autoinflammatory spectrum.
How Autoinflammation Differs From Autoimmunity
The distinction matters because it changes how these conditions are understood and treated. In autoimmune diseases like lupus or rheumatoid arthritis, the adaptive immune system (the slower, more targeted branch that learns to recognize specific threats) mistakenly attacks the body’s own tissues. This process involves self-targeting antibodies and immune cells trained against the wrong target. Blood tests in autoimmune conditions typically show high levels of these autoantibodies.
Autoinflammatory diseases skip that entire process. The innate immune system causes tissue inflammation directly, without involving those specialized antibodies or self-reactive immune cells. There are no autoantibodies driving the attack. Instead, the inflammation comes from an overproduction of signaling molecules called cytokines, particularly one called IL-1 beta, which acts like a fire alarm that won’t stop ringing. This is why autoinflammatory flares can look similar to infections (fever, swelling, redness) even though no pathogen is present.
What Happens Inside the Body During a Flare
At the cellular level, the key players are protein complexes called inflammasomes. Think of these as molecular sensors inside immune cells. Normally, they detect genuine threats like bacteria or cell damage, then activate an enzyme that converts inactive IL-1 beta into its active, inflammation-triggering form. Once released, active IL-1 beta signals surrounding tissues to mount an inflammatory response: blood vessels dilate, immune cells flood in, and you get the heat, swelling, and pain associated with inflammation.
In autoinflammatory diseases, genetic mutations cause these inflammasome sensors to activate without a real threat. One of the most studied sensors, called NLRP3 (also known as cryopyrin), is responsible for an entire family of conditions when it carries gain-of-function mutations. These mutations essentially lower the activation threshold so dramatically that the inflammasome fires constantly or in response to trivial stimuli like cold temperatures. The result is waves of inflammation that come and go, or in severe cases, never fully subside.
Common Symptoms and Flare Patterns
The hallmark feature is periodic fever, episodes of high temperature that alternate with fever-free intervals in a somewhat predictable pattern. Unlike fevers from infections, these don’t respond to antibiotics and often resolve on their own before returning days or weeks later. The pattern and duration of these fever episodes vary by condition, which is one of the clues doctors use to narrow down a diagnosis.
Beyond fever, symptoms commonly include:
- Abdominal pain from inflammation of the lining of the abdominal cavity (serositis)
- Chest pain from inflammation around the lungs or heart
- Joint pain and swelling, often in large joints like knees and ankles
- Skin rashes that vary by condition, from hive-like welts to patches resembling cellulitis
- Muscle pain, fatigue, and flu-like body aches
- Swollen lymph nodes and enlarged liver or spleen
Each condition has its own signature. Some cause periorbital swelling (puffy, swollen skin around the eyes). Others trigger mouth ulcers or gastrointestinal symptoms like vomiting and diarrhea. Because these symptoms overlap with many common illnesses, diagnosis is often delayed, sometimes by years.
Major Autoinflammatory Conditions
Familial Mediterranean Fever (FMF)
FMF is the most common and best-known autoinflammatory disease. It’s caused by mutations in the MEFV gene, which produces a protein called pyrin. Flares typically last 12 to 72 hours and involve fever, intense abdominal pain, chest pain, joint inflammation, and sometimes a distinctive rash on the lower legs. FMF is most prevalent among people of Mediterranean descent, including those with Turkish, Armenian, Arab, and Jewish heritage. It’s usually inherited in an autosomal recessive pattern, meaning a child needs to receive a mutated copy from both parents.
Cryopyrin-Associated Periodic Syndromes (CAPS)
CAPS is actually a spectrum of three conditions caused by mutations in the NLRP3 gene, ranging from mild to severe. The mildest form causes cold-triggered episodes of fever, hive-like rash, and red eyes. The moderate form adds hearing loss from inner-ear inflammation. The most severe form begins at birth and involves chronic meningitis (inflammation of the membranes surrounding the brain), deforming joint disease, and distinctive facial features. All three are inherited in a dominant pattern, meaning one mutated copy of the gene is enough.
TRAPS
TNF receptor-associated periodic syndrome is caused by mutations affecting a receptor for another inflammatory signaling molecule. Flares last longer than FMF, often one to two weeks or more. In a registry of 158 TRAPS patients, the most common symptoms were fever, limb pain, abdominal pain, and rash, each occurring in more than 63% of patients. About 20% also experienced periorbital swelling. TRAPS follows a dominant inheritance pattern.
Systemic Juvenile Idiopathic Arthritis (SJIA)
SJIA sits at the intersection of autoinflammation and autoimmunity. Children with SJIA present with joint inflammation alongside systemic symptoms like spiking fevers, inflammation of the heart lining, swollen lymph nodes, and enlarged organs. It is increasingly recognized as primarily autoinflammatory rather than a classic autoimmune arthritis.
When Symptoms Typically Begin
Most inherited autoinflammatory diseases first appear in childhood, often in the first decade of life. The most severe forms, like the neonatal-onset type of CAPS, are apparent within days of birth. FMF commonly begins before age 20. However, a meaningful number of patients don’t develop symptoms until adulthood, which can make diagnosis even more challenging because doctors may not consider a “childhood disease” in an adult patient. Late onset doesn’t rule out a genetic autoinflammatory condition.
How These Conditions Are Diagnosed
Diagnosis relies on a combination of clinical pattern recognition and laboratory testing. During flares, blood markers of inflammation are sharply elevated, including C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and a protein called serum amyloid A. Between flares, these markers often return to normal, which itself is a useful diagnostic clue.
Genetic testing is central to confirming a diagnosis, particularly for monogenic (single-gene) conditions. The approach typically starts with targeted sequencing of a specific gene when the clinical picture strongly suggests one condition, such as testing the MEFV gene when FMF is suspected. When the picture is less clear, doctors order a gene panel that screens multiple autoinflammatory genes simultaneously using next-generation sequencing technology. For complex or unclear cases, whole exome sequencing can scan the entire protein-coding portion of the genome. This tiered approach helps balance cost and speed against diagnostic thoroughness.
Treatment With IL-1 Blockers
Because overproduction of IL-1 beta drives so many autoinflammatory diseases, treatments that block this molecule have transformed outcomes. Three main biologic medications target IL-1 through different mechanisms: one blocks the receptor that IL-1 binds to, another acts as a decoy receptor that absorbs IL-1 before it can signal, and a third is an antibody that neutralizes IL-1 beta directly. These are administered by injection, either daily, weekly, or every few weeks depending on the specific medication.
For FMF specifically, an older and much less expensive medication, colchicine, remains the first-line treatment. Taken daily as a pill, it reduces both the frequency of flares and the risk of long-term complications. IL-1 blockers are reserved for FMF patients who don’t respond adequately to colchicine.
The response to IL-1-targeted therapy can be dramatic. Patients who experienced flares every few weeks may become essentially symptom-free. For CAPS in particular, early treatment can prevent progressive hearing loss and neurological damage.
The Risk of Amyloidosis
The most serious long-term consequence of uncontrolled autoinflammatory disease is a condition called AA amyloidosis. When inflammation persists over months and years, the liver continuously produces serum amyloid A protein. Over time, fragments of this protein can misfold and deposit in organs as insoluble fibers, gradually destroying normal tissue. The kidneys are the most commonly and severely affected organ, but deposits can also accumulate in the liver, gastrointestinal tract, heart, and nerves.
The stakes of inadequate treatment are starkly illustrated by data from FMF patients. In a study of 960 FMF patients followed over 11 years, those who consistently took colchicine developed kidney-damaging protein spillage (proteinuria) at a rate of just 1.7%. Among those who didn’t take their medication consistently, that number was 48.9%. This gap underscores why lifelong, consistent treatment is so important even during symptom-free intervals. The goal isn’t just to prevent flares but to keep background inflammation low enough to protect organs from irreversible damage.